Todays Report: Today: Revance Therapeutics Inc. (RVNC) CEO L Daniel Browne Sold 12,000 Shares

Today: Revance Therapeutics Inc. (RVNC) CEO L Daniel Browne Sold 12,000 Shares

Revance Therapeutics Inc. (NASDAQ:RVNC) CEO L Daniel Browne sold 12,000 shares of the company’s stock in a transaction on Friday, November 25th. The shares were sold at an average price of $17.92, for a total transaction of $215,040.00. Following the completion of the sale, the chief executive officer now directly owns 208,449 shares in the company, valued at $3,735,406.08. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

L Daniel Browne also recently made the following trade(s): On Wednesday, October 26th, L Daniel Browne sold 12,000 shares of Revance Therapeutics stock. The shares were sold at an average price of $14.85, for a total transaction of $178,200.00.

Revance Therapeutics Inc. (NASDAQ:RVNC) traded down 0.56% during trading on Monday, reaching $17.90. 8,760 shares of the company’s stock were exchanged. The firm’s market capitalization is $510.42 million. Revance Therapeutics Inc. has a 52 week low of $12.35 and a 52 week high of $40.40. The stock has a 50-day moving average price of $15.74 and a 200 day moving average price of $15.48.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.25. Revance Therapeutics had a negative net margin of 28,187.33% and a negative return on equity of 37.31%. During the same quarter in the previous year, the company earned ($0.81) EPS. Equities research analysts forecast that Revance Therapeutics Inc. will post ($3.21) earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in RVNC. JPMorgan Chase & Co. boosted its stake in Revance Therapeutics by 9.9% in the second quarter. JPMorgan Chase & Co. now owns 3,327,022 shares of the biopharmaceutical company’s stock worth $45,247,000 after buying an additional 298,448 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Revance Therapeutics by 7.8% in the second quarter. Bank of New York Mellon Corp now owns 2,118,558 shares of the biopharmaceutical company’s stock worth $28,812,000 after buying an additional 152,383 shares during the last quarter. Polar Capital LLP boosted its stake in Revance Therapeutics by 13.0% in the third quarter. Polar Capital LLP now owns 1,319,871 shares of the biopharmaceutical company’s stock worth $21,392,000 after buying an additional 151,329 shares during the last quarter. BlackRock Fund Advisors boosted its stake in Revance Therapeutics by 10.3% in the third quarter. BlackRock Fund Advisors now owns 1,317,731 shares of the biopharmaceutical company’s stock worth $21,360,000 after buying an additional 123,376 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Revance Therapeutics by 11.3% in the second quarter. Vanguard Group Inc. now owns 783,706 shares of the biopharmaceutical company’s stock worth $10,659,000 after buying an additional 79,366 shares during the last quarter.

Several research firms have recently commented on RVNC. Zacks Investment Research downgraded shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 17th. Brean Capital reissued a “hold” rating on shares of Revance Therapeutics in a report on Friday, August 5th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. Revance Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $36.37.

About Revance Therapeutics

Related posts

Leave a Comment